Search company, investor...
Cameron Health company logo

Cameron Health

Founded Year



Acquired | Acquired

Total Raised




About Cameron Health

Cameron Health, based in San Clemente, California, is a developer of implantable cardiac defibrillators. The company aims to provide a product that is a leadless implantable cardiac defibrillator implanted only in a patient's subcutaneous tissue. The company's implantable cardiac defibrillators are not surgically attached to the heart, thus simplifying the implant procedure and reducing surgical complications. In March 2012, Cameron Health was acquired by Boston Scientific. The valuation of Cameron Health was $150 million. Other terms of the deal were not released.

Headquarters Location

905 Calle Amanecer Suite 300

San Clemente, California, 92673,

United States


Missing: Cameron Health's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cameron Health's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Cameron Health Patents

Cameron Health has filed 172 patents.

The 3 most popular patent topics include:

  • Cardiac arrhythmia
  • Cardiac electrophysiology
  • Cardiology
patents chart

Application Date

Grant Date


Related Topics




Cardiac arrhythmia, Cardiac electrophysiology, Implants (medicine), Cardiology, Antiarrhythmic agents


Application Date


Grant Date



Related Topics

Cardiac arrhythmia, Cardiac electrophysiology, Implants (medicine), Cardiology, Antiarrhythmic agents



Latest Cameron Health News

Cameron Health - Wikipedia, the free encyclopedia

Jul 7, 2013

5 External links Reasons for a minimally invasive approach[ edit ] Every ICD is designed to detect heart rhythms consistent with a catastrophic failure of the body's natural regulation of the heartbeat, which, untreated, could result in death. When an ICD detects a serious arrhythmia , it issues an electrical impulse to the heart muscle, of a magnitude sufficient to cause the heart to revert to a normal rhythm. ICDs with transvenous leads administer this shock to the interior of the heart muscle; the Cameron Health device generates a more powerful shock which can be effective from outside the heart. In the view of Cameron Health, transvenous leads into the heart needlessly complicate the process of implanting a device, and raises other issues and risks which their less invasive approach avoids. [1] The Cameron Health subcutaneous ICD sits outside the ribcage and has no connection to the interior of the heart. The surgical procedure for implantation is minimally invasive as opposed to the traditional procedure of threading leads into the subclavian venous system, through the superior vena cava and into one or more endocardial areas of the heart, a procedure often requiring a cardiologist with specialized training in electrophysiology . [2] In addition to the risks inherent in cardiac surgery, the leads have themselves proved to be a weakness in some ICD designs. [3] According to one estimate, patients with ICDs have a 20 percent chance of lead failure within 10 years, and replacing the leads carries a risk of death of between 2 and 5 percent. [4] Some device manufacturers have had to replace defective leads which exposed implanted individuals to unnecessary shocks or other malfunctions, in some cases possibly resulting in fatalities. [5] [6] The Cameron Health S-ICD has the disadvantage of being somewhat bulkier than existing ICDs. [4] Also, this kind of ICD does not include a pacemaker, which narrows the range of patients for whom it would be appropriate; it is estimated that a majority of patients now receiving combination pacemaker/ICD implants would qualify for a pure ICD. These patients tend to have genetic or other conditions predisposing them to sudden cardiac death due to a failure of the heart of maintain a normal rhythm. [7] Clinical trials and approvals[ edit ] A trial involving 53 patients, who were temporarily implanted with S-ICDs, was reported in 2005 at the European Society of Cardiology Congress. [8] A second series of 55 trial patients was conducted in 2008 and 2009 in 10 centers in Europe and New Zealand . Of the 55 patients, 53 had two instances of fibrillation and in 52 these were successfully converted. These findings were reported to European Union authorities in 2009, and resulted in approval for marketing the device. A study of 300 patients is in progress for US approvals. [4] [9] Small nonrandomized early-phase studies primarily intended to show the feasibility of an entirely subcutaneous ICD were updated, combined and published in May 2010. In this report, the system successfully and consistently detected and converted episodes of ventricular fibrillation that were induced during electrophysiological testing. In the European trial of 55 patients, after 46 patient-years of follow-up, 54 of 55 patients were alive, and the single death was due to renal failure. In this trial the system successfully detected and treated 12 episodes (100%)of spontaneous, sustained ventricular tachyarrhythmia in three patients, prior to the onset of syncope, and with no adverse events. One of the three patients was successfully treated for seven successive episodes of ventricular tachycardia, a condition known as a "VT storm". Financing[ edit ] Boston Scientific acquired an exclusive option to purchase Cameron Health in 2004, and made an undisclosed equity investment in the company at that time. [10] In 2008, several additional investors organized by the investment company Piper Jaffray [11] and including PTV Healthcare Capital, Delphi Ventures, Sorrento Ventures, Three Arch Partners and Versant Ventures provided just over $50 million to finance the continuing operation of the company. [12] In June 2012, Boston Scientific officially acquired Cameron Health for a total sum of $1.3 Billion which will be paid out incrementally as various revenue milestones are achieved. References[ edit ] ^ Bardy, Gust H.; Smith, Hood, Crozier et al. (May 2010). "An Entirely Subcutaneous Implantable Cardioverter–Defibrillator" . N. Engl. J. Med. (New England Journal of Medicine) 363 (1): 36–44. doi : 10.1056/NEJMoa0909545 . PMID   20463331 . Retrieved 13 May 2010. Cite uses deprecated parameter |coauthors= ( help ) ^ Meier, Barry (April 21, 2009). "Study Backs Specialists Implanting Heart Devices" . New York Times. Retrieved 19 January 2010. ^ Jaeger, Fredrick J. "Cardiac Arrhythmias" . Cleveland Clinic. Retrieved 19 January 2010. ^ Meier, B. (March 13, 2009). "Medtronic Links Device for Heart to 13 Deaths" . New York Times. Retrieved 19 January 2010. ^ Burton, Thomas M. (4 February 2010). "Hospitals Dispute Medtronic Data on Wires". Wall Street Journal. pp. D6. |accessdate= requires |url= ( help )

Cameron Health Frequently Asked Questions (FAQ)

  • When was Cameron Health founded?

    Cameron Health was founded in 2000.

  • Where is Cameron Health's headquarters?

    Cameron Health's headquarters is located at 905 Calle Amanecer, San Clemente.

  • What is Cameron Health's latest funding round?

    Cameron Health's latest funding round is Acquired.

  • How much did Cameron Health raise?

    Cameron Health raised a total of $162M.

  • Who are the investors of Cameron Health?

    Investors of Cameron Health include Boston Scientific, Alloy Ventures, Delphi Ventures, Sorrento Associates, Versant Ventures and 9 more.

  • Who are Cameron Health's competitors?

    Competitors of Cameron Health include AngelMed, NeoChord, Dune Medical Devices, Dextera Surgical, Triangle Biosystems and 12 more.

Compare Cameron Health to Competitors

AngelMed Logo

AngelMed develops implantable cardiac monitoring and alerting system to warn cardiac patients of potentially life-threatening heart conditions. It offers heart monitors that track changes in the heart's electrical signal from a standard pacemaker lead. It identifies the symptoms of acute thrombotic occlusions by alerting the patient directly to seek medical attention. The company was founded in 2001 and is based in Eatontown, New Jersey.

NeoChord Logo

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.

Mitralign Logo

Mitralign is developing a catheter-based technology for percutaneous treatment of functional mitral regurgitation. The Mitralign system emulates surgical annuloplasty delivering a series of surgical implants directly into the mitral annulus by means of a catheter. The implants are cinched together, thus reducing the size of the mitral valve annulus and the valve opening.

Axis Surgical Technologies

Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment. Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.

TissueLink Medical

TissueLink Medical is a developer and distributor of medical devices that for surgical procedures. The company's technology aims to eliminate the need for multiple technologies with the potential to reduce operating room and patient recovery time by enabling precise coagulation and cutting, with no excess damage to tissue. These devices will be used in general and thoracic surgical procedures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.